Marc Mathias, MD
Retina Specialist · Aurora, CONPI 1073774121
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Dutch Ophthalmic, USA at 44.4% of the total. Reporting peaked in 2023 at $469 and has fallen 62.6% since, to $175 in 2025. That places this record below the midpoint for retina specialist clinicians in CO, where the typical reported total is $4,083.
Across 17 payments — averaging $69.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dutch Ophthalmic, USA$521
- Carl Zeiss Meditec USA, Inc.$157
- Genentech, Inc.$133
- Kala Pharmaceuticals, Inc.$121
- Johnson & Johnson$91
- Genentech USA, Inc.$72
- plus $79 from 3 others
Across 5 payments — averaging $8960.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$45K
What the payments were for
- Food & beverage$1,174100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dutch Ophthalmic, USA | 5 | $521 |
| Carl Zeiss Meditec USA, Inc. | 2 | $157 |
| Genentech, Inc. | 1 | $133 |
| Kala Pharmaceuticals, Inc. | 1 | $121 |
| Johnson & Johnson | 1 | $91 |
| Genentech USA, Inc. | 3 | $72 |
| Novartis | 2 | $34 |
| Alcon | 1 | $24 |
| Regeneron | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVA, combined machine$342
- TISSUEBLUE$342
- VABYSMO$133
- EYSUVIS$121
- EVA Ophthalmic Surgical System$118
How this compares
$1,174 in reported general payments places this provider in the 15th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 13 | $19,263 |
| Prednisolone Acetate | 64 | $2,407 |
| Ketorolac Tromethamine | 65 | $2,256 |
| Fluorometholone | 13 | $823 |
| Dorzolamide Hcl | 32 | $683 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 37 | $620 |
| Latanoprost | 34 | $427 |
| MoxifloxacinMoxifloxacin Hcl | 18 | $356 |
| Brimonidine Tartrate | 35 | $221 |
| Timolol Maleate | 11 | $143 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Aurora
- Talisa ForestAurora$84K
- Lynn HassmanAurora$16K
- Zachary KoretzAurora$14K
- Ross ChodAurora$10K
- Niranjan ManoharanAurora$9K
- Amit ReddyAurora$4K
- Rachel ChenAurora$4K
- Naresh MandavaAurora$3K
- Frank SiringoAurora$3K
- Abraham HangAurora$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.